Factor P Antibody (Monoclonal - #1)

A murine monoclonal antibody to an epitope on Factor P.


Product Specifications

Citations 10
Clonality

Monoclonal

Immunogen Purified human protein.
Applications See citations and technical data sheet for application info.
Concentration 1.0-1.2 mg/mL
Conjugate Unconjugated
Cross Reactivity

Human

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A233
Catalog Number (CE) N/A
Size 100 µl
Price (USD) $395.00
Price (EURO) 360,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcustomerservice@quidelortho.com
EU EmailEMEACustomerService@quidelortho.com

Specifications

Description

A murine monoclonal antibody to an epitope on Factor P.

Size 100 µl
Concentration

1.0-1.2 mg/mL

Applications See citations and technical data sheet for application info.
Form Liquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide.
Clonality Monoclonal
Immunogen Purified human protein.
Conjugate Unconjugated
Cross Reactivity Human
Isotype IgG1k
Purity ≥ 95% by SDS PAGE
Source

Mouse

Specificity This monoclonal antibody was raised against purified Factor P. It inhibits the function of Factor P.
Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

The function of Properdin (Factor P) is to stabilize the alternative pathway convertase. Its binding to C3bBb extends the half-life of the complex. The concentration in plasma is approximately 20 μg/mL. Factor P has a molecular weight of 224 kDa, consisting of four identical chains of approximately 53 kDa molecular weight. The alternative complement pathway provides innate protection against microbial agents in the absence of specific antibody. The activation of this complement pathway can be triggered by a variety of substances, including microbial polysaccharides or lipids, gram-negative bacterial lipopolysaccharides, and surface determinants present on some viruses, parasites, virally infected mammalian cells and cancer cells. In autoimmune diseases, the alternative complement pathway may contribute directly to tissue damage.

Citations

Title Year Applications Sample Species Sample Sample Details

Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans

2011

WB

Human

Serum

Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein

2012

FC

Human

Serum

Meningococcal infected

The role of properdin in zymosan- and Escherichia coli-induced complement activation

2013

FC

Human

Serum

A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples

2014

ELISA

Human

Plasma

Properdin binding to complement activating surfaces depends on initial C3b deposition

2017

ELISA, WB

Human

Serum

Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo

2017

WB

Human

Plasma

SPIO nanoworms

Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo

2017

WB

Human

Serum

SPIO nanoworms

Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy

2019

ELISA

Human

Plasma

Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy

2019

ELISA

Human

Serum

Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation

2020

Hemolytic Assay

Rabbit

Red Blood Cells

Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration

2024

ELISA

Human

Serum

Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration

2024

ELISA

Human

Serum